---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-204493"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:51:45.312551+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology acquires Pionyr in all-stock deal, receives ~$43M net cash

## Summary
- Ikena issued 1.8M common shares and 4.2M Series A convertible preferred shares at $7.15/share for all of Pionyr.
- Pionyr contributed ~$43M net cash; Ikena to use funds to accelerate IK-930 and IK-595 clinical programs.
- Pionyr shareholders (including Gilead Sciences) hold ~12% of Ikena post-deal; management and board unchanged.
- CVRs grant Pionyr holders 50% of net proceeds from any monetization of Pionyr legacy assets within two years.
- Ikena expects initial IK-930 clinical data in 2023 and IK-595 IND filing later in 2023.

## SEC filing metadata
- accession: 0001193125-23-204493
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 2.01, 3.02, 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/d469204d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-204493
- JSON: https://secwatch.observer/filing/0001193125-23-204493.json
- Plain text: https://secwatch.observer/filing/0001193125-23-204493.txt

## Key facts
- Governance Changes
  ImageneBio, Inc.: Filed Certificate of Designation establishing Series A Non-Voting Convertible Preferred Stock (effective 2023-08-04).
  - Change: charter amendment
  - Effective: 2023-08-04
  source text: On August 4, 2023, Ikena filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger referenced in Item 1.01 above.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- M&A Transactions
  ImageneBio, Inc. completed an acquisition involving Pionyr Immunotherapeutics, Inc. (closed 2023-08-04).
  - Action: acquisition
  - Counterparty: Pionyr Immunotherapeutics, Inc.
  - Closing: 2023-08-04
  source text: On August 4, 2023, Ikena completed its business combination with Pionyr.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- Material Agreements
  ImageneBio, Inc. entered into Support Agreements with certain stockholders of Ikena.
  - Action: entry
  - Agreement: merger
  - Counterparty: certain stockholders of Ikena
  source text: In connection with the execution of the Merger Agreement, Ikena and Pionyr entered into stockholder support agreements (the “ Support Agreements ”) with certain stockholders of Ikena.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- Material Agreements
  ImageneBio, Inc. entered into Merger Agreement with Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc..
  - Action: entry
  - Agreement: merger
  - Counterparty: Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc.
  source text: Under the terms of the Merger Agreement, outstanding options to acquire Pionyr Common Stock (each, a “ Company Option ”) that had an exercise price greater than the Per Share Cash Consideration (as defined in the Merger Agreement) were cancelled
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- Material Agreements
  ImageneBio, Inc. entered into CVR Agreement with Ikena and the Rights Agent.
  - Action: entry
  - Counterparty: Ikena and the Rights Agent
  source text: In connection with the Merger, Ikena and the Rights Agent (as defined therein) entered into a contingent value rights agreement (the “ CVR Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm
- Material Agreements
  ImageneBio, Inc. entered into Lock-up Agreements with certain Pionyr securityholders.
  - Action: entry
  - Agreement: merger
  - Counterparty: certain Pionyr securityholders
  source text: Concurrently and in connection with the execution of the Merger Agreement, certain Pionyr securityholders as of immediately prior to the Merger entered into lock-up agreements with Ikena and Pionyr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.